Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • A new research has suggested that losing even one night of sleep can alter your genes, and increased risk of obesity and type 2 diabetes. Swedish researchers at Uppsala University and the Karolinska Institutet revealed that genes that control the biological clocks in cells throughout the body are altered even after one night of sleep loss. The study appeared in the Journal of Clinical Endocrinology and Metabolism.

  • Parkinson's disease (PD) is a chronic and progressive disorder of the central nervous system that affects movement. It is often characterized by tremors. Researchers have now found a link between a class of drugs used to treat diabetes and protection against PD. The study published  in PLOS Medicine.

  • (Business Wire India) Wipro Limited, a leading global information technology, consulting, and business process services company, today announced that it has been selected by DSM, a global, science based company active in health, nutrition and materials, as its strategic IT partner to provide Workplace Services.

  • Researchers at the University of Tokyo have discovered a long-overlooked process important for converting a long, string-like DNA molecule into a chromosome. This finding gives us a better understanding of the mechanism of how cells store safely genetic material, DNA.

  • Shri J P Nadda, Minister of Health and Family Welfare held a review meeting with senior officials of Health Ministry in the backdrop of recent outbreak of Japanese Encephalitis (JE) in Assam. He stated that the Director General of Health Services has been directed to immediately rush a team of experts to Assam to assist and advise the State health authorities in clinical management of the cases.

  • Biogen and the Parkinson’s Institute and Clinical Center announced the formation of a strategic alliance focused on enhancing the understanding of the underlying biology of Parkinson’s disease (PD) and the creation of novel tools and programs that could accelerate research and the development of new PD treatments. The agreement will combine the unique clinical expertise and data of the Institute with Biogen’s focus on neurodegenerative disease and approach to clinical development.

  • Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd today announced an exclusive license and collaboration agreement for the development and global commercialisation rights, except South Korea, China and Hong Kong, of HM61713, a novel 3rd generation EGFR targeted therapy for the treatment of EGFR mutation positive lung cancer. Under the terms of the agreement Hanmi will receive an initial payment of USD 50 million and is entitled to potential milestone payments of USD 680 million plus tiered double-digit royalties on future net sales. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the U.S., and other customary closing conditions.

  • Malaria is caused by infection with the parasite Plasmodium falciparum (Pf).  According to the World Health Organization (WHO) malaria currently infects more than 200 million people worldwide and accounts for more than 500,000 deaths per year. Scientists have now developed a new drug that shows hope for stopping the deadly malaria. The study is published in the Journal of Experimental Medicine.

Subscribe to Pharma News